title: Temporal gene expression in the hippocampus and peripheral organs to endotoxin-induced systemic inflammatory response in caspase-1-deficient mice.
abstract: OBJECTIVE
  Caspase-1 (casp1), a key protease involved in the systemic inflammatory response syndrome (SIRS), controls the brain expression of a set of eight genes: Nos2 and Ptgs2 (nitric oxide synthase 2 and prostaglandin-endoperoxide synthase 2, two inducible enzymes), Cxcl1 and Cxcl10 (C-X-C motif chemokine ligand 1 and ligand 10), Tgtp and Gbp2 (T cell-specific GTPase 1 and guanylate-binding protein 2, two GTPases), Adamts1 (a disintegrin-like and metallopeptidase with thrombospondin type 1 motif, 1, a metalloprotease) and Il1rn (interleukin-1 receptor antagonist). Our objective was to ascertain whether casp1 also controlled the peripheral expression of these genes and, if so, to compare their central versus peripheral patterns of gene expression in immune and endocrine tissues during SIRS.
  
  
  METHODS
  Wild-type (wt) and casp1 knockout (casp1(-/-)) mice were injected with either saline or a high dose of endotoxin/lipopolysaccharide (LPS; 800 μg/mice i.p.). Saline-injected mice were immediately euthanized after injection, whereas LPS-injected mice were sacrificed 6 and 12 h after LPS administration. Hippocampal, splenic and adrenal gene expressions were determined by real-time PCR.
  
  
  RESULTS
  Overall, casp1(-/-) mice showed a lower inflammatory response than wt mice. The expression levels of powerful proinflammatory factors such as Nos2 and Ptgs2 was reduced in casp1(-/-) mice. Moreover, a hierarchical clustering analysis aimed at studying patterns of gene coexpression revealed large alterations in the hippocampal pattern of casp1(-/-) mice. Surprisingly, the expression of Adamts1 was increased in the hippocampus and adrenals of casp1(-/-) mice.
  
  
  CONCLUSIONS
  The resilience of casp1(-/-) mice to SIRS lethality is associated with a lower inflammatory response, loss of hippocampal gene coexpression patterns, and increased hippocampal Adamts1 gene expression. The latter might be beneficial for casp1(-/-) mice, since ADAMTS1 is likely to play a role in neuronal plasticity. The mechanisms described here may help the development of either novel biomarkers or therapeutic targets against SIRS/sepsis.
authors: Genomics and Predictive Medicine Group, Genome Biology Department, John Curtin School of Medical Research, Australian National University, Canberra, A.C.T., Australia.
authors: Claudio Alberto
authors: CA
authors: Mastronardi
authors: Gilberto
authors: G
authors: Paz-Filho
authors: Martina
authors: M
authors: Zanoni
authors: Nicolas
authors: N
authors: Molano-González
authors: Mauricio
authors: M
authors: Arcos-Burgos
authors: Julio
authors: J
authors: Licinio
authors: Ma-Li
authors: ML
authors: Wong
mesh_terms: D000311:Adrenal Glands / Q000378:metabolism*; D000818:Animals; D020170:Caspase 1 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D015870:Gene Expression; D006624:Hippocampus / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D013154:Spleen / Q000378:metabolism; D018746:Systemic Inflammatory Response Syndrome / Q000139:chemically induced / Q000378:metabolism*
chemical_list: D008070:Lipopolysaccharides; D020170:Caspase 1
references: Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6046-51
references: 24715728
references: Am J Physiol. 1999 Nov;277(5 Pt 2):R1435-43
references: 10564217
references: J Clin Invest. 2000 May;105(10):1345-52
references: 10811842
references: Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8681-6
references: 10890909
references: Neuroimmunomodulation. 2000;8(2):91-7
references: 10965234
references: Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14720-5
references: 11724949
references: Neuroimmunomodulation. 2001;9(3):148-56
references: 11752888
references: Endocrinology. 2002 May;143(5):1571-4
references: 11956136
references: N Engl J Med. 2003 Jan 9;348(2):138-50
references: 12519925
references: Proc Natl Acad Sci U S A. 1990 May;87(9):3629-32
references: 2333306
references: Ann Med. 2002;34(7-8):614-23
references: 12553502
references: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14241-6
references: 14623955
references: Eur J Pharmacol. 1990 Jul 17;182(3):591-5
references: 2226626
references: Crit Care Med. 2004 Jan;32(1):21-30
references: 14707556
references: Blood. 2004 Jul 15;104(2):314-20
references: 15044249
references: Trends Immunol. 2004 Nov;25(11):601-9
references: 15489189
references: Crit Care Med. 1991 Nov;19(11):1339-47
references: 1935150
references: Lancet. 1991 Dec 21-28;338(8782-8783):1557-8
references: 1720856
references: Cardiovasc Res. 1994 Jan;28(1):34-9
references: 7509259
references: Neuroendocrinology. 1994 Aug;60(2):124-33
references: 7969769
references: J Immunol. 1995 Feb 15;154(4):1724-34
references: 7836757
references: Cell. 1995 Feb 10;80(3):401-11
references: 7859282
references: J Leukoc Biol. 1995 Mar;57(3):477-83
references: 7884320
references: Circ Shock. 1994 Sep;44(1):1-8
references: 7704933
references: N Engl J Med. 1995 May 18;332(20):1351-62
references: 7715646
references: Nat Med. 1996 May;2(5):581-4
references: 8616720
references: Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11008-13
references: 8855299
references: Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):227-32
references: 8990190
references: N Engl J Med. 1997 Mar 27;336(13):912-8
references: 9070471
references: Crit Care Med. 1997 Jul;25(7):1115-24
references: 9233735
references: Crit Care Med. 1998 Apr;26(4):660-7
references: 9559602
references: Endocr Rev. 1998 Jun;19(3):269-301
references: 9626555
references: J Immunol. 1998 Sep 1;161(5):2348-55
references: 9725230
references: Crit Care Med. 1999 Apr;27(4):699-707
references: 10321658
references: Crit Care. 2004 Dec;8(6):R474-82
references: 15566594
references: Am J Physiol Lung Cell Mol Physiol. 2005 Jan;288(1):L3-15
references: 15591040
references: Neuroimmunomodulation. 2005;12(3):182-8
references: 15905627
references: J Pharmacol Exp Ther. 2006 Jan;316(1):271-8
references: 16183703
references: Bioinformatics. 2006 Jun 15;22(12):1540-2
references: 16595560
references: Endocr Metab Immune Disord Drug Targets. 2006 Jun;6(2):137-42
references: 16787287
references: J Clin Invest. 2007 Feb;117(2):289-96
references: 17273548
references: Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7205-10
references: 17409187
references: Neuroendocrinology. 2007;85(4):207-15
references: 17541258
references: Crit Care Med. 2008 Jul;36(7):1999-2007
references: 18552688
references: Neuroimmunomodulation. 2010;17(6):359-68
references: 20516717
references: Nature. 2011 Nov 3;479(7371):117-21
references: 22002608
references: Mediators Inflamm. 2012;2012:696897
references: 22665954
references: PLoS One. 2012;7(10):e47226
references: 23071766
references: J Proteome Res. 2012 Nov 2;11(11):5338-49
references: 23025351
references: Am J Respir Crit Care Med. 2014 Feb 1;189(3):282-91
references: 24456467